{"brief_title": "Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients", "brief_summary": "The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.", "condition": ["Open-angle Glaucoma", "Ocular Hypertension"], "intervention_type": ["Drug", "Other", "Drug", "Drug", "Drug"], "intervention_name": ["AL-12182 0.003% Ophthalmic Solution", "AL-12182 Ophthalmic Solution Vehicle", "Latanoprost 0.005% Ophthalmic Solution", "AL-12182 0.01% Ophthalmic Solution", "AL-12182 0.03% Ophthalmic Solution"], "description": ["Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension", "Placebo", "Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension", "Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension", "Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension"], "arm_group_label": ["AL-12182 0.003%", "AL-12182 Solution Vehicle", "Latanoprost", "AL-12182 0.01%", "AL-12182 0.03%"], "criteria": "Inclusion Criteria: - 18 years or older. - Diagnosis of open-angle glaucoma or ocular hypertension. - LogMAR visual acuity not worse than 0.6. - Other protocol-defined inclusion criteria may apply. Exclusion Criteria: - Clinically relevant ophthalmic or systemic conditions. - Other protocol-defined exclusion criteria may apply.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "POAG", "mesh_term": ["Hypertension", "Glaucoma", "Glaucoma, Open-Angle", "Ocular Hypertension", "Pharmaceutical Solutions", "Latanoprost", "Ophthalmic Solutions"], "id": "NCT00069706"}